

**PREPARED FOR THE REGISTRAR
CSPC (PHARMACY) LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 10 APRIL 2019**

CSPC (Pharmacy) Limited

Contents

Company Information	<u>1</u>
Balance Sheet	<u>2</u>
Notes to the Financial Statements	<u>3 to 8</u>

CSPC (Pharmacy) Limited

Company Information

Directors	Mr C R Badham Mrs L M Badham Mr P S S Badham Mrs H J Ireland
Registered office	The Old Farmers Arms Evesham Road Bishops Cleeve Cheltenham GL52 8SA
Accountants	Hazlewoods LLP Staverton Court Staverton Cheltenham GL51 0UX

CSPC (Pharmacy) Limited**(Registration number: 06128246)****Balance Sheet as at 10 April 2019**

	Note	10 April 2019 £	(As restated) 10 April 2018 £
Fixed assets			
Intangible assets	<u>5</u>	-	642,850
Tangible assets	<u>6</u>	-	582,682
		-	1,225,532
Current assets			
Stocks		-	124,893
Debtors	<u>7</u>	1,000	303,534
Cash at bank and in hand		-	1,365
		1,000	429,792
Creditors: Amounts falling due within one year	<u>8</u>	-	(1,905,129)
Net current assets/(liabilities)		1,000	(1,475,337)
Net assets/(liabilities)		<u>1,000</u>	<u>(249,805)</u>
Capital and reserves			
Called up share capital		1,000	1,000
Profit and loss account		-	(250,805)
Total equity		<u>1,000</u>	<u>(249,805)</u>

For the financial year ending 10 April 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 8 January 2020 and signed on its behalf by:

.....
Mr C R Badham
Director

The notes on pages 3 to 8 form an integral part of these financial statements.

CSPC (Pharmacy) Limited

Notes to the Financial Statements for the Year Ended 10 April 2019

1 General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
The Old Farmers Arms
Evesham Road
Bishops Cleeve
Cheltenham
GL52 8SA
England

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Critical accounting judgements and key sources of estimation uncertainty

In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company.

The company recognises revenue when:

The amount of revenue can be reliably measured;

it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

CSPC (Pharmacy) Limited

Notes to the Financial Statements for the Year Ended 10 April 2019

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Land and buildings	Over Lease term and Straight line over 15 years
Fixtures, Fittings, equipment and motor vehicles	Straight line over 15 years

Goodwill

Goodwill is amortised over its useful life, estimated by the directors to be 20 years.

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company's interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.

Negative goodwill arising on an acquisition is recognised on the face of the balance sheet on the acquisition date and subsequently the excess up to the fair value of non-monetary assets acquired is recognised in profit or loss in the periods in which the non-monetary assets are recovered.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

CSPC (Pharmacy) Limited

Notes to the Financial Statements for the Year Ended 10 April 2019

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments

Classification

Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Impairment

Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

CSPC (Pharmacy) Limited

Notes to the Financial Statements for the Year Ended 10 April 2019

3 Staff numbers

The average number of persons employed by the company (including directors) during the year, was as follows:

	Year ended 10 April 2019 No.	1 April 2017 to 10 April 2018 No.
Average number of employees	<u>4</u>	<u>20</u>

4 Prior period adjustment

Following the agreement of the financial figures in relation to the the last trading period under the former shareholders the profit and loss for the period to 10 April 2018 and balance sheet as at 10 April 2018 was restated to include a reduction in sales of £12,260 and to write off a loan by £116,667. The effect of these adjustments was to reduce the loss for the period by £104,407 to £294,913 and reduce the net liabilities from £354,212 to £249,805.

5 Intangible assets

	Goodwill £
Cost	
At 11 April 2018	926,566
Transfer on hive up	<u>(926,566)</u>
At 10 April 2019	<u>-</u>
Amortisation	
At 11 April 2018	283,716
Transfer on hive up	<u>(283,716)</u>
At 10 April 2019	<u>-</u>
Carrying amount	
At 10 April 2019	<u>-</u>
At 10 April 2018	<u>642,850</u>

CSPC (Pharmacy) Limited

Notes to the Financial Statements for the Year Ended 10 April 2019

6 Tangible assets

	Land and buildings £	Furniture, fittings and equipment £	Motor vehicles £	Total £
Cost				
At 11 April 2018	597,417	156,352	8,995	762,764
Transferred on hive up	(597,417)	(156,352)	(8,995)	(762,764)
At 10 April 2019	-	-	-	-
Depreciation				
At 11 April 2018	131,577	39,510	8,995	180,082
Transferred on hive up	(131,577)	(39,510)	(8,995)	(180,082)
At 10 April 2019	-	-	-	-
Carrying amount				
At 10 April 2019	-	-	-	-
At 10 April 2018	465,840	116,842	-	582,682

7 Debtors

	Note	10 April 2019 £	(As restated) 10 April 2018 £
Trade debtors		-	143,962
Amounts owed by related parties	10	1,000	42,581
Other debtors		-	116,991
		1,000	303,534

8 Creditors

Creditors: amounts falling due within one year

	Note	10 April 2019 £	(As restated) 10 April 2018 £
Due within one year			
Loans and borrowings	9	-	1,241,515
Trade creditors		-	232,135
Social security and other taxes		-	12,973
Other creditors		-	418,506
		-	1,905,129

CSPC (Pharmacy) Limited

Notes to the Financial Statements for the Year Ended 10 April 2019

9 Loans and borrowings

	2019 £	2018 £
Current loans and borrowings		
Bank loans	-	920,000
Bank overdrafts	-	321,515
	<u>-</u>	<u>1,241,515</u>

The bank loans and overdrafts were secured against the assets of the company.

10 Related party transactions

Badham Pharmacy Limited

(Parent)

During the year, Badham Pharmacy Limited made a loan to the company of £250,805 (2018 - £Nil). The loan made to the company of £250,805, (2018 - £Nil) was written off. At the balance sheet date the company was owed £1,000 by Badham Pharmacy Limited (2018 - £Nil). There are no fixed repayment terms and no interest is charged on the loan.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.